Sees FY13 CRM sales $2.675B-$2.715B. Says midpoint of CRM sales guidance continues to assume CRM sales will decline approximately 4% for FY13. Sees Q2 AF product sales $225M-$240M, FY13 AF product sales $938M-$968M; midpoint of AF product sales guidance assumes sales will increase approximately 9% for FY13. Sees Q2 cardiovascular sales $325M-$345M, sees FY13 cardiovascular sales $1.32B-$1.35B; assumes a constant currency increase over 2012 of 3%-5%. Sees Q2 neuromodulation sales $100M-$110M, FY13 sales $425M-$450M. Says changes in assumptions regarding currency exchange rates reduced total forecasted sales for the remainder of 2013 by approximately $60M-$70M. Sees FY gross profit margin 72.2%-72.7%. Sees FY effective tax rate 20.8%-21.3%.